Summary
Becton Dickinson & Co. (BDX) reported its third-quarter and nine-month results for fiscal year 2002, showing revenue growth driven by its Medical and Clinical Laboratory Solutions segments. While overall revenue increased, profit margins were impacted by factors such as increased manufacturing costs, special charges related to a restructuring program, and a shift in product mix. The company also adopted new accounting standards, notably SFAS No. 141 and 142, which eliminated goodwill amortization and positively impacted diluted earnings per share. Financially, BDX demonstrated solid cash flow from operations, though it was partially offset by a significant pension plan contribution. The company's debt-to-capital ratio improved, indicating a stronger balance sheet. Investments in capital expenditures continued, albeit at a lower pace than the prior year. Investors should note the company's ongoing efforts to optimize manufacturing, manage special charges, and navigate potential impacts from legal proceedings, while also benefiting from the change in accounting for goodwill.
Key Highlights
- 1Total revenues increased by 6% to $998.5 million for the third quarter and by 7% to $2.96 billion for the nine months ended June 30, 2002.
- 2The company adopted SFAS No. 141 and 142, ceasing the amortization of goodwill and indefinite-lived intangible assets, which provided a benefit of approximately 7.5 cents to diluted EPS for the nine-month period.
- 3Special charges of $12 million were recorded in the third quarter and $22 million for the nine months related to a manufacturing restructuring program in the Medical segment.
- 4Cash provided by operating activities remained strong at $532.4 million for the nine months, though slightly impacted by a $100 million pension plan contribution.
- 5BDX improved its debt-to-capital ratio to 32.7% from 36.4% year-over-year, reflecting a stronger balance sheet.
- 6The company is facing significant legal proceedings, including an antitrust case filed by Retractable Technologies, Inc. and class action lawsuits related to needlesticks, with trials and appeals ongoing.
- 7A potential divestiture of the critical care product line was announced, which could result in a substantial pre-tax loss estimated between $35 to $40 million if consummated.